Data showed that deaths from opioid overdoses in teens aged 14 to 18 increased by a staggering 94% between 2019 and 2020 and by an additional 20% between 2020 and 2021.

Per the data, the biggest driver of the deaths was the fentanyl in the drug supply, imported from China. The synthetic opioid that’s 80x – 100x more powerful than morphine has been linked to 77% of all adolescent opioid overdose deaths since 2021. During the timespan examined by the study, adolescent opioid deaths increased by a staggering 350%.

The number of forensic drug reports testing positive for fentanyl has skyrocketed in recent years from under 20,000 in 2015 to 117,045 in 2020. A recent study from the National Institutes of Health found that the number of individual fentanyl pills seized by law enforcement increased nearly 50x from the first quarter of 2018 to the last quarter of 2021.

Activists say the surging deaths highlight the need for “urgent action”.

Advocates say that the record highs in overdose deaths highlight the importance of adopting new strategies to combat the opiate epidemic.

“Urgent action is needed to address America’s spiraling overdose crisis, including expanding access to opioid addiction treatment and investing in harm reduction,” the Commonwealth Fund, a nonprofit health care research organization, wrote in a February report, “but these lifesaving tools continue to be underutilized and resistance remains strong in many areas of the country.”

In other news related to the opioid pandemic, the NYT revealed earlier this week that McKinsey, the American consulting giant that has already been exposed for advising Perdue Pharma – the maker of Oxycontin, the drug widely credited with sparking the opioid epidemic – also advised the FDA on drug approvals while it was also advising Perdue. What’s worse, many of the same consultants responsible for advising Perdue also advised the FDA.

Jeff Smith, a partner with the influential consulting firm McKinsey & Company, accepted a highly sensitive assignment in December 2017. The opioid manufacturer Purdue Pharma, beleaguered and in financial trouble, wanted to revamp its business, and an executive there sought out Dr. Smith.

Over the following weeks, he traveled to Purdue’s offices in Stamford, Conn., meeting and dining with executives. His team reviewed business plans and evaluated new drugs that Purdue hoped would help move the company beyond the turmoil associated with OxyContin, its addictive painkiller that medical experts say helped to spark the opioid epidemic.

The documents reviewed by the Times were apparently leaked by the House Committee on Oversight and Reform

A review by The New York Times of thousands of internal McKinsey documents found that the firm repeatedly allowed employees who served pharmaceutical companies, including opioid makers, to also consult for the F.D.A., the drug industry’s primary government regulator.

And, the documents show, McKinsey touted that inside access in pitches to private clients. In an email in 2014 to Purdue’s chief executive, a McKinsey consultant highlighted the firm’s work for the F.D.A. and stressed “who we know and what we know.”

Perdue, and its owners, the Sackler Family, have agreed to pay billions in fines as a result of a spate of lawsuits brought by the states, federal government and other parties.

But clearly, the opioid pandemic isn’t yet over. And much of the illegally manufactured fentanyl that finds its way into the American drug supply originates in China, a trade that has continued to thrive despite President Xi’s promises to crack down.